BR112021021106A2 - Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona - Google Patents

Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona

Info

Publication number
BR112021021106A2
BR112021021106A2 BR112021021106A BR112021021106A BR112021021106A2 BR 112021021106 A2 BR112021021106 A2 BR 112021021106A2 BR 112021021106 A BR112021021106 A BR 112021021106A BR 112021021106 A BR112021021106 A BR 112021021106A BR 112021021106 A2 BR112021021106 A2 BR 112021021106A2
Authority
BR
Brazil
Prior art keywords
crystalline form
fumarate
plk4
methoxyspiro
dimethylmorpholino
Prior art date
Application number
BR112021021106A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Bray Mark
Sze-Wan Li
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of BR112021021106A2 publication Critical patent/BR112021021106A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112021021106A 2019-04-24 2020-04-23 Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona BR112021021106A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837858P 2019-04-24 2019-04-24
PCT/CA2020/050535 WO2020215155A1 (en) 2019-04-24 2020-04-23 Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate

Publications (1)

Publication Number Publication Date
BR112021021106A2 true BR112021021106A2 (pt) 2021-12-14

Family

ID=72940551

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021106A BR112021021106A2 (pt) 2019-04-24 2020-04-23 Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona

Country Status (16)

Country Link
US (1) US12325700B2 (https=)
EP (1) EP3959209A4 (https=)
JP (1) JP7705351B2 (https=)
KR (1) KR20220004102A (https=)
CN (1) CN113966330B (https=)
AU (1) AU2020264143A1 (https=)
BR (1) BR112021021106A2 (https=)
CA (1) CA3137191A1 (https=)
EA (1) EA202192903A1 (https=)
IL (1) IL287394A (https=)
MA (1) MA55767A (https=)
MX (1) MX2021012993A (https=)
SA (1) SA521430647B1 (https=)
SG (1) SG11202111003UA (https=)
TW (1) TWI862582B (https=)
WO (1) WO2020215155A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7717842B2 (ja) 2021-05-11 2025-08-04 オリック ファーマシューティカルズ,インク. ポロ様キナーゼ4阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
EP2205241B1 (en) 2007-09-25 2014-05-21 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
US8586598B2 (en) 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
ES2706066T3 (es) 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
US20140051679A1 (en) 2011-10-12 2014-02-20 Univeristy Health Networks Kinase inhibitors and method of treating cancer with same
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer
HUE043194T2 (hu) * 2013-10-18 2019-08-28 Univ Health Network PLK-4 inhibitor sója és kristályformái

Also Published As

Publication number Publication date
WO2020215155A8 (en) 2020-11-26
TW202104216A (zh) 2021-02-01
JP7705351B2 (ja) 2025-07-09
KR20220004102A (ko) 2022-01-11
TWI862582B (zh) 2024-11-21
SA521430647B1 (ar) 2024-01-27
MX2021012993A (es) 2021-12-10
MA55767A (fr) 2022-03-02
IL287394A (en) 2021-12-01
US12325700B2 (en) 2025-06-10
WO2020215155A1 (en) 2020-10-29
EP3959209A4 (en) 2022-12-28
AU2020264143A1 (en) 2021-10-28
EA202192903A1 (ru) 2022-02-09
CA3137191A1 (en) 2020-10-29
EP3959209A1 (en) 2022-03-02
SG11202111003UA (en) 2021-11-29
US20220204494A1 (en) 2022-06-30
CN113966330A (zh) 2022-01-21
JP2022530028A (ja) 2022-06-27
CN113966330B (zh) 2024-09-13

Similar Documents

Publication Publication Date Title
AR079257A1 (es) Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
AR091138A1 (es) Proceso para la preparacion de n-[5-(3,5-difluorobencil)-1h-indazol-3-il]-4-(4-metilpiperazin-1-il)-2-(tetrahidropiran-4-ilamino)-benzamida
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
PY19106776A (es) FORMAS POLIMÓRFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
UY31083A1 (es) Derivados de sulfoximinas para la inhibicion de b-secretasa
MX2020009612A (es) Polimorfos de sal de calcio novedosos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
ATE475415T1 (de) Neue salze des wirkstoffs rasagilin
UY31084A1 (es) Compuestos de azaindol para la inhibicion de b-secretasa
KR950700258A (ko) 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체(heterocyclic carbonic acid derivatives which bind to retinoid receptors(rar))
CY1118107T1 (el) Παραγωγα ετεροαρυλιου ως διαμορφωτες αλφα7 nachr
MY207696A (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
AR029570A1 (es) Nueva forma cristalina gamma de la sal de terbutilamina de perindopril, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
BR112013006594A2 (pt) composto, composição farmacêutica, método de tratamento de um distúrbio, e, uso de um composto
WO2008125600A3 (en) Pyrazole derivatives as p2x7 modulators
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
UA83720C2 (ru) Кристаллическая форма v агомелатина, способ ее получения и фармацевтическая композиция, которая ее содержит
BR112014031616A2 (pt) compostos de fenoxietil piperidina
MX2011008959A (es) Compuestos carbonatos de anti-biopelicula para su uso en composiciones para el cuidado oral.
SV2010003770A (es) Composicion y proceso- 356
BR112014026305A2 (pt) derivado de quinazolidinadiona
AR084862A1 (es) Formas solidas de inhibidor de girasa (r) 1-etil-3-[5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
BR112021021106A2 (pt) Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
RU2014140336A (ru) Иммунологически полезные соли аргинина
BR112015026967A2 (pt) compostos fenoxietil di-hidro-1h-isoquinolina

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]